Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. - Wikidata - awgldk - TriplyDB

Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.

Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.

http://www.wikidata.org/entity/Q44298526

about

Circulating Tumor Cells in the Adenocarcinoma of the Esophagus Endoscopic options for early stage esophageal cancer Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities.Esophageal cancer: staging system and guidelines for staging and treatment.Ovarian mass mimicking malignancy: a case report Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.Current strategies in chemoradiation for esophageal cancer.The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction.SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer Imaging of esophageal cancer.Imaging and cancer: a review.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT.FDG-PET parameters as prognostic factor in esophageal cancer patients: a review.Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers.Imaging response assessment in oncology Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.Locally advanced cancer of the esophagus, current treatment strategies, and future directions Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation.PET/CT and hepatic radiation injury in esophageal cancer patients.Current treatment options for the management of esophageal cancer.Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.Role of positron emission tomography in the (re-)staging of oesophageal cancer.(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.Potential impact of (18)FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagus Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.Surgical management of esophagogastric junction tumors.Functional PET imaging in cancer drug development.Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma The 100 most cited articles investigating the radiological staging of oesophageal and junctional cancer: a bibliometric analysis.Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma.Esophageal cancer: current and emerging therapy modalities.Diabetes and PET Scans: Only Part of a Bigger Problem.Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.

P2860

Q26741429-F7637C33-BD4F-4B5C-B6F6-86678D558DB2 Q26998802-E67C84CE-641E-421C-920F-79BDE949711E Q30436049-4529AF9F-3FA7-4B97-B251-5899ACF73738 Q33235431-CCF9D063-4BB5-4BB3-BB00-4118C87AFEC2 Q33612658-8DCCAE96-6B7A-493C-A12B-E085C6AF9402 Q33680811-69504549-2D5D-4301-AC29-FFA5711A7F5A Q33704074-0B234FE4-28BC-417B-8780-8400B5F69262 Q33728359-47B45F3D-BB28-4D89-BD73-15B7E70A3512 Q33797361-E04B8AEE-1CF8-4FC9-9CE0-EB156001270A Q33820782-94ED015B-5146-4CCF-89A3-D8270EA6DD23 Q33902475-99EEB3A8-B4FF-44CB-8604-6FD3C164FBD8 Q34061012-F1BA5996-484A-462F-9317-71E20EE0883B Q34104159-93C0975A-940E-4758-8537-548C59BA18A8 Q34164634-83AB5ED5-2346-4724-9104-97731DD4CC99 Q34533348-7209BDC9-11E3-475B-B1D8-E78097EE0DA6 Q34977050-B4B21289-CFAB-4EDF-9271-CB8505DFB5D1 Q34978457-13261914-AB4E-482D-90F1-8DD8286D5346 Q35230789-142CFF99-90A2-44B4-91BB-97EC50A894B7 Q35332601-A92643D1-D232-4718-9793-8F63D0AE03DF Q35445146-F793F7D3-DCCF-4BF0-9DD9-07F45A9B4C2C Q35583933-BE656CC4-B8B5-4DDD-82EB-3C6DB02A6147 Q35650697-C29333D3-EF2C-48FA-95E0-D8E98D7DC715 Q35761121-BD774876-9CD0-409D-84FD-162CE1A2BA85 Q35985417-6691A329-EAAA-4831-9672-851C9554FDE4 Q36022348-03C10DD5-11A9-4658-968B-5694AB8F1B9F Q36295210-439419B3-B9A1-4672-94D9-E851BF635448 Q36393867-81F5B891-A2B3-4F4B-AA0B-FAFF935ADA88 Q36427789-DF6317F5-1FCF-459F-B87D-E6705DDA6401 Q36510702-8EBC4370-0D5A-4FAA-AFC1-29EA2F79E13E Q36611842-8ECCF41F-609A-471C-BE1C-4B573CC7327E Q36623646-ED35F239-4EB2-4AC9-89B6-A0EF42C13CD5 Q36626093-A259538A-8A84-4325-B99A-3AC6D5EE1220 Q36640053-727A18AB-2560-4570-8AE1-457FAB0B6D84 Q36768305-45C1C18D-F46B-4EBC-B957-D6F426DEEF5D Q36810301-184889E8-F181-4753-BD0A-98BE1130EC9C Q37116282-CC345C98-C42C-48A3-86D8-910CB483445F Q37204680-0071D6D5-1100-4FB0-9B6E-18BBC633DD23 Q37256825-A058CF99-C5B9-42D1-940B-0365E6A99A61 Q37337139-29A8F39E-6751-4D45-B19D-601634EB274A Q37338260-0EBE0D10-6B66-4B0C-B9DF-5847A1AC6FFE

P2860

Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.

http://www.wikidata.org/entity/Q44298526

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Whole body 18FDG-PET and the r ...... esults of a prospective trial.

@en

Whole body 18FDG-PET and the r ...... esults of a prospective trial.

@nl

type

label

Whole body 18FDG-PET and the r ...... esults of a prospective trial.

@en

Whole body 18FDG-PET and the r ...... esults of a prospective trial.

@nl

prefLabel

Whole body 18FDG-PET and the r ...... esults of a prospective trial.

@en

Whole body 18FDG-PET and the r ...... esults of a prospective trial.

@nl

P1433

Q44298526-FCD37F97-A0FE-4CDC-B6E3-CF7C9B2ABD28

P1476

Q44298526-B4CECDE2-2542-40AA-9EAD-A20D1BD5E68C

P2093

Q44298526-1DAC973F-33E0-4DE3-A2B3-0EE962A2BEA3

Q44298526-35DF042A-FADF-485E-8758-300AC2B2F82E

Q44298526-3BE5519A-FD35-4FBF-9F18-8BBE5596FE9F

Q44298526-422AD2E4-4383-454E-9E85-581C9EE6C4FA

Q44298526-4DE00444-75EF-4D49-84CC-D0CA572EAB12

Q44298526-6FB7FADD-80C9-4FF2-826D-DB626117FF35

Q44298526-879A25C0-410B-4C2F-9847-E3E7B4B6B829

Q44298526-9B676E8E-FE39-4D99-AED7-65A1F7E33FC0

Q44298526-B1FFC3DE-4684-42C1-922F-EFE175EF7AD3

Q44298526-BE045A56-5536-44D0-8653-6424920B3B13

P304

Q44298526-540D343D-CEB6-4B5C-800E-3F0F53828A3A

P31

Q44298526-8A2F6E0D-2EEB-495F-9475-E457CD4EDE3A

P356

Q44298526-C8D17BD4-BC96-4F1E-B5E1-C6DF091EDA4D

P407

Q44298526-BABE9DE0-AAB8-4997-8CD1-193ECFEC7B36

P433

Q44298526-5FF6BABD-AE65-45C7-9E9E-59429AB4317D

P478

Q44298526-86193855-1FDB-4605-B35B-4B429B0830A1

P50

Q44298526-3EA07A0D-AC36-4C34-8C3F-DD2E4133250D

P577

Q44298526-DE17CBD5-C033-44CD-AEBA-10C95AF87655

P698

Q44298526-61D01D9E-FD95-40AB-8C63-E4391AE352F8

P356

JCO.2003.04.013

P1433

Journal of Clinical Oncology

P1476

Whole body 18FDG-PET and the r ...... results of a prospective trial

@en

P2093

Alan Turnbull

http://www.w3.org/2001/XMLSchema#string

Bruce D Minsky

http://www.w3.org/2001/XMLSchema#string

David Ilson

http://www.w3.org/2001/XMLSchema#string

Heng Koong

http://www.w3.org/2001/XMLSchema#string

Manjit S Bains

http://www.w3.org/2001/XMLSchema#string

Marc Gollub

http://www.w3.org/2001/XMLSchema#string

Maureen Zakowski

http://www.w3.org/2001/XMLSchema#string

Mithat Gonen

http://www.w3.org/2001/XMLSchema#string

Robert Ginsberg

http://www.w3.org/2001/XMLSchema#string

Robert J Downey

http://www.w3.org/2001/XMLSchema#string

P304

428-432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.04.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Valerie W Rusch

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12560430

http://www.w3.org/2001/XMLSchema#string